Amicus, Shire to Develop and Commercialize Compounds

Amicus Therapeutics will collaborate with a Shire subsidiary to develop Amicus’ three lead pharmacological chaperone compounds for lysosomal storage disorders.

Shire will receive rights to commercialize these products outside the U.S., Amicus said.

The collaboration includes Amigal (migalastat hydrochloride), which is in Phase II trials for Fabry disease, Plicera (isofagomine tartrate), which is in Phase II clinical trials for Gaucher disease, and AT2220 (deoxynojirimycin), which the company is currently studying in Phase I trials for Pompe disease.